Bevacomb 5 mg/80 mg Filmdragerad tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

bevacomb 5 mg/80 mg filmdragerad tablett

teva b.v. - amlodipinbesilat; valsartan - filmdragerad tablett - 5 mg/80 mg - amlodipinbesilat 6,95 mg aktiv substans; valsartan 80 mg aktiv substans

Bevacomb 5 mg/160 mg Filmdragerad tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

bevacomb 5 mg/160 mg filmdragerad tablett

teva b.v. - amlodipinbesilat; valsartan - filmdragerad tablett - 5 mg/160 mg - valsartan 160 mg aktiv substans; amlodipinbesilat 6,95 mg aktiv substans

Bevacomb 10 mg/160 mg Filmdragerad tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

bevacomb 10 mg/160 mg filmdragerad tablett

teva b.v. - amlodipinbesilat; valsartan - filmdragerad tablett - 10 mg/160 mg - valsartan 160 mg aktiv substans; amlodipinbesilat 13,9 mg aktiv substans

Fusacomb Easyhaler 50 mikrogram/250 mikrogram/dos Inhalationspulver Sverige - svenska - Läkemedelsverket (Medical Products Agency)

fusacomb easyhaler 50 mikrogram/250 mikrogram/dos inhalationspulver

orion corporation - flutikasonpropionat; salmeterolxinafoat - inhalationspulver - 50 mikrogram/250 mikrogram/dos - salmeterolxinafoat 73 mikrog aktiv substans; laktosmonohydrat hjälpämne; flutikasonpropionat 250 mikrog aktiv substans

Fusacomb Easyhaler 50 mikrogram/500 mikrogram/dos Inhalationspulver Sverige - svenska - Läkemedelsverket (Medical Products Agency)

fusacomb easyhaler 50 mikrogram/500 mikrogram/dos inhalationspulver

orion corporation - flutikasonpropionat; salmeterolxinafoat - inhalationspulver - 50 mikrogram/500 mikrogram/dos - laktosmonohydrat hjälpämne; flutikasonpropionat 500 mikrog aktiv substans; salmeterolxinafoat 73 mikrog aktiv substans

Ciprofloxacin MDS 250 mg Filmdragerad tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

ciprofloxacin mds 250 mg filmdragerad tablett

medical drug supplies ltd - ciprofloxacinhydroklorid (monohydrat) - filmdragerad tablett - 250 mg - ciprofloxacinhydroklorid (monohydrat) 291,1 mg aktiv substans; laktosmonohydrat hjälpämne - ciprofloxacin

Ciprofloxacin MDS 500 mg Filmdragerad tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

ciprofloxacin mds 500 mg filmdragerad tablett

medical drug supplies ltd - ciprofloxacinhydroklorid (monohydrat) - filmdragerad tablett - 500 mg - ciprofloxacinhydroklorid (monohydrat) 582,2 mg aktiv substans; laktosmonohydrat hjälpämne - ciprofloxacin

Ciprofloxacin MDS 750 mg Filmdragerad tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

ciprofloxacin mds 750 mg filmdragerad tablett

medical drug supplies ltd - ciprofloxacinhydroklorid (monohydrat) - filmdragerad tablett - 750 mg - ciprofloxacinhydroklorid (monohydrat) 873,3 mg aktiv substans; laktosmonohydrat hjälpämne - ciprofloxacin

Eucreas Europeiska unionen - svenska - EMA (European Medicines Agency)

eucreas

novartis europharm limited - vildagliptin, metformin hydroklorid - diabetes mellitus, typ 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Icandra (previously Vildagliptin / metformin hydrochloride Novartis) Europeiska unionen - svenska - EMA (European Medicines Agency)

icandra (previously vildagliptin / metformin hydrochloride novartis)

novartis europharm limited - vildagliptin, metformin hydroklorid - diabetes mellitus, typ 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 och 5. 1 för tillgänglig data på olika kombinationer).